Skip to Main Content

Paper Details

Response to dual HER2 blockade in a patient with HER3-mutant metastatic breast cancer.
Ann Oncol
21
2015
G284R, HER2, HER2-negative breast cancer, HER2-negative synchronous liver metastasis, HER3, HER3 G284R, HER3 G284R mutation, HER3 activating mutations, HER3-mutant metastatic breast cancer, PATIENTS, breast cancers, lapatinib, liver, man, patient, phospho, phospho-AKT, phospho-rpS6, trastuzumab
Author NameAffiliation
Charlotte K Y NgMemorial Sloan Kettering Cancer Center
Salvatore PiscuoglioMemorial Sloan Kettering Cancer Center
Rita A SakrMemorial Sloan Kettering Cancer Center
Raymond S LimMemorial Sloan Kettering Cancer Center
Larry NortonMemorial Sloan Kettering Cancer Center
Larry NortonMemorial Sloan Kettering Cancer Center
Britta WeigeltMemorial Sloan Kettering Cancer Center
Jorge S Reis-FilhoMemorial Sloan Kettering Cancer Center
  • 1 - 8

Datasets

Release 1.2